(2-chlorothiazol-4-yl)methanamine hydrochloride | 1350362-35-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (2-chlorothiazol-4-yl)methanamine hydrochloride
• 英文别名: (2-Chlorothiazol-4-yl)methanamine hydrochloride；(2-chloro-1,3-thiazol-4-yl)methanamine;hydrochloride
• CAS: 1350362-35-4
• 化学式: C₄H₅ClN₂S*ClH
• 分子量: 185.077
• InChiKey: AYXNYLIHRNSIJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.68
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  硫脲 、 1,3-二氯丙酮 以 丙酮 为溶剂， 反应 4.0h， 以71%的产率得到(2-chlorothiazol-4-yl)methanamine hydrochloride
  参考文献：
  名称：

  Novel Orally Active Antimalarial Thiazoles

  摘要：

  An aminomethylthiazole pyrazole carboxamide lead 3 with good in vitro antiplasmodial activity [IC50: 0.08 mu M (K1, chloroquine and multidrug resistant strain) and 0.07 mu M (NF54, chloroquine sensitive strain)] and microsomal metabolic stability was identified from whole cell screening of a SoftFocus kinase library. Compound 3 also exhibited in vivo activity in the P. berghei mouse model at 4 x 50 mg/kg administration via the oral route, showing 99.5% activity and 9 days survival and showed low in vitro cytotoxicity. Pharmacokinetic studies in rats revealed good oral bioavailability (51% at 22 mg/kg) with a moderate rate of absorption, reasonable half-life (t(1/2) 3 h), and high volume of distribution with moderately high plasma and blood clearance after IV administration. Toward toxicity profiling, 3 exhibited moderate potential to inhibit CYP1A2 (IC50 = 1.5 mu M) and 2D6 (IC50 = 0.4 mu M) as well as having a potential hERG liability (IC50 = 3.7 mu M).

  DOI：

  10.1021/jm201108k

文献信息

• Novel Orally Active Antimalarial Thiazoles
  作者：Diego González Cabrera、Frederic Douelle、Tzu-Shean Feng、Aloysius T. Nchinda、Yassir Younis、Karen L. White、Quoc Wu、Eileen Ryan、Jeremy N. Burrows、David Waterson、Michael J. Witty、Sergio Wittlin、Susan A. Charman、Kelly Chibale

  DOI：10.1021/jm201108k

  日期：2011.11.10

  An aminomethylthiazole pyrazole carboxamide lead 3 with good in vitro antiplasmodial activity [IC50: 0.08 mu M (K1, chloroquine and multidrug resistant strain) and 0.07 mu M (NF54, chloroquine sensitive strain)] and microsomal metabolic stability was identified from whole cell screening of a SoftFocus kinase library. Compound 3 also exhibited in vivo activity in the P. berghei mouse model at 4 x 50 mg/kg administration via the oral route, showing 99.5% activity and 9 days survival and showed low in vitro cytotoxicity. Pharmacokinetic studies in rats revealed good oral bioavailability (51% at 22 mg/kg) with a moderate rate of absorption, reasonable half-life (t(1/2) 3 h), and high volume of distribution with moderately high plasma and blood clearance after IV administration. Toward toxicity profiling, 3 exhibited moderate potential to inhibit CYP1A2 (IC50 = 1.5 mu M) and 2D6 (IC50 = 0.4 mu M) as well as having a potential hERG liability (IC50 = 3.7 mu M).